Cornerstone Therapeutics Inc.(CRTX)- NASDAQ
CRTX is defunct.
  • Aug. 6, 2013, 3:35 PM
    • Cornerstone Therapeutics (CRTX +4.2%) moves higher on a solid Q2, reporting earnings of $0.19 per share and beating consensus estimates of $0.12.
    • Revenues were $40.4M, up 88% Y/Y and above the analyst estimate of $35.79M. In the same period last year, the company reported $0.17 loss per share on revenues of $21.5M.
    • Gross margin of 75%, compared to 59% in Q212, primarily due to the addition of CARDENE I.V., as well as growth in net product sales resulting from price increases and lower estimated rates for certain sales allowances.
    | Aug. 6, 2013, 3:35 PM
  • Jun. 13, 2013, 12:45 PM
    Midday top 10 gainers: BLC +27%. GCI +26%. CERE +19%. TVL +17%. LRAD +14%. GTN +13%. ENVI +13%. VSTM +12%. PXLW +12%. OVRL +11%.
    Midday top 10 Losers: CHNG.PK -19%. HMTV -16%. EAC -15%. SGOC -14%. CREG -13%. CRTX -11%. RFIL -11%. VELT -10%. ECTE -10%. JVA -9%.
    | Jun. 13, 2013, 12:45 PM | 1 Comment
  • Jun. 13, 2013, 10:49 AM

    Cornerstone Therapeutics (CRTX -11.5%) plummets after saying it has received a letter from Exela Pharma regarding the filing of an NDA for a product similar to CRTX's CARDENE I.V. Premixed Injection. The company says it will "pursue all available legal and regulatory avenues in defense" of CARDENE. (PR)

    | Jun. 13, 2013, 10:49 AM
  • Mar. 21, 2013, 11:23 AM

    Cornerstone Therapeutics (CRTX -2.8%) says it's retained Lazard to act as its independent financial advisor and Clifford Chance to act as its independent legal counsel to assist the Special Committee in considering purchasing the company's common stock that it does not already own for a cash price of between $6.40 and $6.70 per share.

    | Mar. 21, 2013, 11:23 AM
  • Feb. 20, 2013, 12:45 PM
    Midday top 10 gainers: NVGN +46%. IMMY +33%. IKNX +29%. NTSP +29%. CRTX +22%. LZB +17%. CHLN +16%. RVLT +15%. CMGE +14%. TCX +14%.
    Midday top 10 losers: HNR -39%. MM -36%. GMXR -19%. MEIL -19%. JAXB -18%. ANAD -16%. ODP -14%. ONCY -13%. BONE -13%. COBR -12%.
    | Feb. 20, 2013, 12:45 PM
  • Feb. 19, 2013, 5:35 PM
    Cornerstone Therapeutics (CRTX) +20% AH to $6.55 after disclosing Italy's Chiesi Therapeutics, which already owns 65% of Cornerstone, delivered a letter yesterday offering to buy the rest of it for $6.40-$6.70/share in cash. (13D)
    | Feb. 19, 2013, 5:35 PM
  • Sep. 13, 2012, 2:12 PM

    Cornerstone Therapeutics (CRTX -17%) shares plunge after an FDA advisory panel votes against approval of lixivaptan for the treatment of low sodium levels in the blood associated with heart failure. Shares resumed trading at 2:00 after a halt at the open.

    | Sep. 13, 2012, 2:12 PM
  • Sep. 11, 2012, 9:36 AM

    FDA reviewer Nancy Xu says Cornerstone's (CRTX +5.3%) Lixivaptan drug should be approved to treat low sodium levels in the blood due to a condition that causes the body to have excess water. However, Xu says Lixivaptan shouldn't be authorized for heart-failure patients. An FDA advisory panel is due to meet on Thursday.

    | Sep. 11, 2012, 9:36 AM
  • Sep. 11, 2012, 9:10 AM
    Premarket gainers: WSB +91%. SNSS +48%. CTIC +15%. NOK +7%. CRTX +7%. RBS +6%. PSTI +5%.
    Losers: NAVB -31%. PPO -12%. PANW -8%. SQNM -7%. PPHM -6%.
    | Sep. 11, 2012, 9:10 AM
  • Mar. 13, 2012, 9:02 AM

    Cornerstone Therapeutics (CRTX) +9.3% premarket after announcing that the FDA has accepted a new drug application for CRTX 080, its product candidate for the treatment of hyponatremia.

    | Mar. 13, 2012, 9:02 AM
Company Description
Cornerstone Therapeutics, Inc., is a specialty pharmaceutical company which commercializes products for the hospital and adjacent specialty markets.
Sector: Healthcare
Industry: Biotechnology
Country: United States